Anzeige
Mehr »
Dienstag, 19.05.2026 - Börsentäglich über 12.000 News
Während viele nur über AI sprechen, baut dieses Unternehmen bereits die Infrastruktur dafür
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
1.137 Leser
Artikel bewerten:
(2)

Engage Venture Partners Announces Lead Investment in VOCxi Health

The Minnesota-based medtech venture capital firm marks continued growth of its research-driven model leveraging deep industry expertise and an inclusive investment vehicle.

MINNEAPOLIS, MN / ACCESSWIRE / December 21, 2022 / Engage Venture Partners, a venture capital (VC) firm committed to building a funding community for early-stage medical technology companies and their investors, announces its investment in VOCxi Health. This marks the third investment for Engage since the firm's launch earlier this year and the first time it has led a funding round.

Engage was founded in July 2022 to provide clients access to extensively vetted investment opportunities in the medical device, digital health, and healthcare software sectors. The firm's Special Purpose Vehicles (SPVs) allow investors to choose the startups they wish to fund. This flexible, investor-friendly model also has lower fees than traditionally structured venture capital funds.

The most recent investment is a $1.6 million SAFE (simple agreement for future equity) seed round for VOCxi Health. This financing, raised from a group of 39 individual and institutional investors in 10 states, nearly doubled the firm's largest previous investment - a signal of successful growth for the well-established medtech venture partners. "Fundraising is one of the most important efforts for a startup, and I am so pleased with how Engage led our development funding round," said Ping Yeh, CEO VOCxi Health.

Minnesota-based VOCxi Health is a breath diagnostics company focused on accurate, non-invasive, mobile disease identification. Born out of years of research at the University of Minnesota and a global medical device leader, VOCxi's patented smart mask is designed to measure disease from thousands of volatile organic compounds in just one minute of breath, making late-stage diagnoses a thing of the past.

Engage Partner Morgan Evans will join VOCxi's board of directors, bringing her industry expertise to support the investment. Evans, a medtech founder and executive, brings extensive experience in regulatory pathways, FDA clearance, and commercialization. "After a months-long due diligence process, we had such confidence in the incredible team that VOCxi has assembled, paired with its breakthrough technology that has been years in the making, that we felt very confident taking the role of lead investor," said Evans.

"Engage's knowledge and thoughtful advice was extremely helpful as we approached our fundraising. Through their strong network of highly engaged investors, they contributed a significant portion of this first round," Yeh said, adding "We are also thrilled to have Morgan bring her substantial experience and expertise to our board of directors."

To learn more about Engage and investment opportunities, email investors@engagevp.com.

About Engage Venture Partners
Minneapolis-based and Woman-Owned, Engage Venture Partners is a research-driven venture capital firm focused on early-stage medtech investments. With extensive healthcare and medical device industry knowledge, and decades of experience in investing and startup operations, Engage delivers a flexible and investor-friendly structure utilizing Special Purpose Vehicles (SPVs). Accredited investors are invited to join the Engage Investor Network, which requires neither a fee to join nor a minimum investment commitment. Email investors@engagevp.com to learn more.

ENGAGE'S SERVICES, ENGAGE ADMINISTERED INVESTMENT OPPORTUNITIES, AND ENGAGE MATERIALS ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DO NOT CONSTITUTE INVESTMENT, LEGAL, OR TAX ADVICE. NOTHING PROVIDED BY ENGAGE CONSTITUTES A SOLICITATION, RECOMMENDATION, ENDORSEMENT, OR OFFER BY ANY ENGAGE PARTY, THE TARGET, OR ANY THIRD-PARTY SERVICE PROVIDER TO BUY OR SELL ANY SECURITIES OR OTHER FINANCIAL INSTRUMENTS IN MINNESOTA OR IN IN ANY OTHER JURISDICTION IN WHICH SUCH SOLICITATION OR OFFER WOULD BE UNLAWFUL UNDER THE SECURITIES LAWS OF SUCH JURISDICTION. THERE ARE RISKS ASSOCIATED WITH INVESTING IN SECURITIES, INCLUDING WITHOUT LIMITATION, THE RISK OF COMPLETELY LOSING ANY AND ALL INVESTED AMOUNTS.

Media Contact:
Liz Goar
liz@npccs.com

SOURCE: Engage Venture Partners

View source version on accesswire.com:
https://www.accesswire.com/732818/Engage-Venture-Partners-Announces-Lead-Investment-in-VOCxi-Health

© 2022 ACCESS Newswire
Vergessen Sie Gold, Silber und Öl: Nächste Megarallye startet!
Die Märkte feiern neue Rekorde – doch im Hintergrund braut sich eine Entwicklung zusammen, die alles verändern könnte. Die anhaltende Sperrung der Straße von Hormus sorgt laut IEA für eine der größten Energiekrisen aller Zeiten. Gleichzeitig schießen die Preise für Düngemittel und Agrarrohstoffe bereits nach oben.

Damit droht ein perfekter Sturm: steigende Energiepreise, explodierende Produktionskosten und ein möglicher Super-El-Nino, der weltweit Ernten gefährdet. Erste Auswirkungen sind längst sichtbar – Weizen, Soja und Kakao verteuern sich deutlich, während Lebensmittelpreise vor dem nächsten Sprung stehen könnten.

Für Anleger bedeutet das nicht nur Risiken, sondern enorme Chancen. Denn während klassische Märkte unter Druck geraten könnten, entsteht auf den Feldern und Plantagen der nächste große Rohstoffzyklus. Wer sich jetzt richtig positioniert, kann von einer Entwicklung profitieren, die weit über Öl und Metalle hinausgeht.

In unserem aktuellen Spezialreport stellen wir drei Aktien vor, die besonders aussichtsreich sind, um von diesem Trend zu profitieren – solide positioniert, strategisch relevant und mit erheblichem Aufwärtspotenzial.



Jetzt den kostenlosen Report sichern – bevor der Agrar-Boom voll durchschlägt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.